Plus Therapeutics subsidiary clears key Medicare milestone
Paves way for CNS cancer test rollout
Paves way for CNS cancer test rollout
Advanced image-free robotic platform to support greater precision, personalised planning, and improved patient outcomes
The clearance marks a pivotal step forward for the company as it pushes deeper into AI-driven diagnostics and expands its clinical footprint in point-of-care imaging
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held
Investment will support LifeSigns’ global expansion across Southeast Asia and GCC markets
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
Subscribe To Our Newsletter & Stay Updated